The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve ...

Novavax Inc. closed 73.09% below its 52-week high of $23.86, which the company achieved on June 6th.

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional ...

Novavax’s COVID-19 vaccine could soon receive full approval from the United States Food and Drug Administration.

Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the ...

While Vaxart can proceed with its study, fellow COVID-19 vaccine developers GeoVax and Novavax continue to be hamstrung by ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...